Cannabis Biotech Eyes “CURE” for Cancer

There will soon be new research on how specific medical cannabis strains can help kids with different types of cancer, thanks to a partnership between leading pharmaceutical and cancer technologies organizations.

The partners in research include CURE Pharmaceutical (OTCQB:CURR), CannaKids and Technion Israel Institute of Technology. The organizations will collaborate to research how different cannabinoid compounds within cannabis strains can be used to treat various subtypes of cancer.

With this research, cancer patients could potentially find a more perfect match with the medical cannabis strains that can best help their specific symptoms.

Tracy Ryan, CEO of CannaKids, said “We are in a brave new world of plant based cannabinoid medicines, and it is an honor to be working alongside such brilliant minds.” CannaKids has developed a full line of cannabinoid therapies to help aid patients, particularly children.

Ryan visited the Technion team in Israel in search of help for her own daughter’s rare brain tumor. “I was elated to find groundbreaking research already taking place in a federally legal environment,” Ryan said. Technion is known for innovation in medicine, as a leading science and technology university with three Nobel Prize winners.

Rob Davidson, CEO of CURE Pharmaceutical, which is new to the pharmaceutical cannabis sector, said “This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in our goal to bring new cancer-fighting cannabinoid molecules to market.”

Davidson said studying the antitumor effects of phytocannabinoids and terpenes in medical cannabis could expand medical cannabis options and make the drugs available for other forms of cancer, and provide more informed treatment options.

Technion’s lab group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells.

Several studies have demonstrated the use of cannabinoids in being able to regress different cancer types, according to Technion. This research collaboration will determine which cannabis strains might be used to tackle different cancer cells, and what cannabinoid compounds within the plant are responsible for the ability to kill these cells.

“Together these options further efforts toward the creation of personalized medicine,” Davidson said.

Written by: Jesse Carpender

Trafficroots Analysis Pixel